| Company Name: |
AN PharmaTech Co Ltd
|
| Tel: |
86(21)68097365 |
| Email: |
sales@anpharma.net |
| Products Intro: |
CAS:122957-06-6
|
Modipafant manufacturers
- Modipafant
-
- $1520.00 / 25mg
-
2024-10-28
- CAS:122957-06-6
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | Modipafant Basic information |
| Product Name: | Modipafant | | Synonyms: | Uk 80067;Modipafant;ethyl (4R)-4-(2-chlorophenyl)-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyridin-1-yl)phenyl]-5-(pyridin-2-ylcarbamoyl)-1,4-dihydropyridine-3-carboxylate;3-Pyridinecarboxylic acid, 4-(2-chlorophenyl)-1,4-dihydro-6-methyl-2-[4-(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl]-5-[(2-pyridinylamino)carbonyl]-, ethyl ester, (4R)- | | CAS: | 122957-06-6 | | MF: | C34H29ClN6O3 | | MW: | 605.09 | | EINECS: | | | Product Categories: | | | Mol File: | 122957-06-6.mol |  |
| | Modipafant Chemical Properties |
| density | 1.34±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | pka | 12.14±0.70(Predicted) |
| | Modipafant Usage And Synthesis |
| Uses | Modipafant (UK-80067), the (+)-enantiomer of UK-74505, is a potent, orally active, and selective platelet-activating factor (PAF) antagonist. Modipafant exhibits approximately double the intrinsic potency of UK-74505[1][2]. | | References | [1] Kuitert LM, et al. Effect of a novel potent platelet-activating factor antagonist, modipafant, in clinical asthma. Am J Respir Crit Care Med. 1995;151(5):1331-1335. DOI:10.1164/ajrccm.151.5.7735582
[2] Jezequel SG, et al, a new PAF antagonist: pharmacokinetics and disposition in rat, dog and man. Xenobiotica. 1996;26(9):963-975. DOI:10.3109/00498259609052498 |
| | Modipafant Preparation Products And Raw materials |
|